Skip to search formSkip to main contentSkip to account menu

rosiglitazone

Known as: Rosiglitazona, (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion, 5-((4-(2-methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate 
An agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic and anti-inflammatory activities. In addition to its… 
National Institutes of Health

Related topics

Related topics

16 relations

Narrower (3)

AvandametAvandiaBRL 49653
Diabetes Mellitus, Non-Insulin-DependentDrug AllergyLiver diseasesMetformin / rosiglitazone

Broader (3)

Hypoglycemic AgentsThiazolesThiazolidinediones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Managing Diabetes and Liver Disease Association Guidelines (Consensus) Development
2013
2013
Determinants of the combined use of external beam radiotherapy and brachytherapy for low‐risk, clinically localized prostate cancer
Prostate cancer treatment choices have been shown to vary by physician and patient characteristics. For patients with low‐risk… 
2010
2010
Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
Background In May 2007 Nissen and Wolski reported the results of a meta-analysis showing an association between use of… 
2010
2010
Synthesis And Evaluation Of Newer Quinoline Derivatives Of Thiazolidinediones For Their Antidiabetic Activity
In view of various biological activities of both thiazolidinediones and quinoline derivatives like antidiabetic, antifungal… 
2007
2007
Weighing up the evidence
A meta-analysis of clinical trials for the diabetes drug Avandia has hinted at possible cardiovascular risks; but how clear is… 
2005
2005
Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers
Background— Antidiabetic thiazolidinediones (TZDs), like rosiglitazone or pioglitazone, improve endothelial function in patients… 
2005
2005
Mild, reversible pancytopenia induced by rosiglitazone.
Rosiglitazone, a member of the thiazolidinediones, is a well-established oral antidiabetic agent. It reduces plasma glucose… 
2003
2003
Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway.
AIM To study the effect of rosiglitazone (RSG) on insulin secretion in isolated pancreatic islets under chronic exposure to free… 
2003
2003
Simultaneous HPTLC Determination Of Gliclazide And Rosiglitazone In Tablets
An HPTLC method has been developed for the simultaneous estimation of gliclazide and rosiglitazone from its combined dosage form… 
Review
2001
Review
2001
Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials.
Diabetes markedly increases the risk of coronary artery disease and death, but is underrecognised as a cardiovascular risk factor…